Dr. Alison Allan’s research lab is on the 4th floor of the London Health Sciences Centre (LHSC). The lab is a realm of true science
This research team aims to understand the interactions between CD44+ breast cancer cells and CD44-interacting proteins produced by the lung microenvironment in order to determine how this helps migration and growth in the lung as part of the metastatic process. We are investigating whether we can use an inhaled drug delivery approach to directly inhibit CD44-interacting proteins in the lung as an effective strategy for reducing breast cancer metastasis as well as toxic side effects. By gaining a greater understanding of the underlying biology and therapeutic potential of lung-derived factors in breast cancer metastasis, we have the potential to positively impact breast cancer patient survival in the future.
Using breast cancer cell lines, we will determine the role of a PARP3 inhibitor in drug resistance and its efficacy in combination with conventional treatments utilizing biochemical and DNA techniques in test tubes and animal models.